Avacta Group (LSE:AVCT) Other Financing: £-2.18 Mil (TTM As of Dec. 2025)


LSE:AVCT Avacta Group PLC LSE:AVCT
28 GF Score
Price £0.74
GF Value £0.49
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Avacta Group Other Financing?

Avacta Group LSE:AVCT -3.29% 28 Other Financing is £-2.18 Mil as of Dec. 2025. GuruFocus rates LSE:AVCT with a GF Score™ of 28/100 and a GF Value™ of £0.49 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Avacta Group's Other Financing for the six months ended in Dec. 2025 was £-2.37 Mil.

Avacta Group's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was £-2.18 Mil.

Avacta Group Other Financing Historical Data

* Premium members only.

The historical data trend for Avacta Group's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avacta Group Other Financing Chart

Avacta Group Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -4.03 -0.86 -2.32 -4.21

Avacta Group Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 -2.02 -0.30 0.19 -2.37
LSE:AVCT
28GF Score
Avacta Group PLC LSE:AVCT
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avacta Group Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-2.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of £-2.18 Mil mean?
Avacta Group (LSE:AVCT) has a Other Financing of £-2.18 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Avacta Group and its competitors.
Is Avacta Group's Other Financing too high?
Avacta Group's current Other Financing is £-2.18 Mil. Overall, Avacta Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Other Financing compare to VRTX and REGN?
Avacta Group's Other Financing of £-2.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Avacta Group and its competitors. Avacta Group's current Other Financing is £-2.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (LSE:AVCT) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.49, compared to a current price of £0.74 — trading 50% above its estimated fair value. The current Other Financing is £-2.18 Mil. Avacta Group's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Avacta Group (LSE:AVCT), the current Other Financing is £-2.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avacta Group (LSE:AVCT) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of £0.74 is trading 50% above its estimated GF Value™ of £0.49. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for LSE:AVCT:

  • Other Financing: £-2.18 Mil
  • GF Value™: £0.49 vs. price of £0.74 (50% above fair value)
  • GF Score™: 28/100 with 9 warning signs

No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCTF:USARTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score

Get the complete analysis for LSE:AVCT

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.74
Price
£0.49
GF Value